Oral Estradiol Cost in Vermont 2026

What Does Oral Estradiol Actually Cost in Vermont Right Now?

Vermont retail pharmacies charge an average of $15 per month for generic oral estradiol tablets in 2026 when patients pay cash without insurance. The manufacturer list price for branded and generic versions sits near $40 per month, but that number rarely reflects what anyone pays at the counter. Using a GoodRx or RxSaver discount card at chains such as Walgreens, CVS, or Kinney Drugs in Burlington, Montpelier, or Rutland typically brings the 30-tablet supply of estradiol 1 mg down to the $10 to $18 range depending on the specific pharmacy. FDA-approved labeling for estradiol tablets is available on the FDA accessdata portal.

Generic estradiol has been off-patent for decades. The 0.5 mg, 1 mg, and 2 mg tablet strengths are manufactured by multiple companies including Amneal, Teva, and Mylan. That supply competition keeps prices low in Vermont, as in every other state. A 90-day supply at a GoodRx price runs approximately $25 to $45 at most Vermont retail locations, reducing the effective monthly cost further. A 2022 analysis in JAMA Internal Medicine confirmed that generic hormone therapy pricing has remained stable relative to inflation across most U.S. markets.

Patients who qualify for Vermont's 340B program through federally qualified health centers (FQHCs) in the state, such as Community Health Centers of Burlington, may pay even less. 340B pricing for estradiol tablets can drop below $5 per month for eligible low-income patients. The Health Resources and Services Administration (HRSA) maintains the 340B database and eligibility criteria.

Price varies by pharmacy, by tablet strength, and by whether the patient uses a manufacturer savings card. Check GoodRx or the pharmacy's direct coupon before paying list price.

Does Vermont Medicaid Cover Oral Estradiol?

Vermont Medicaid (Green Mountain Care) covers oral estradiol for moderate-to-severe vasomotor symptoms of menopause, but requires prior authorization (PA). The PA process asks the prescriber to document symptom severity, confirm the absence of contraindications such as active thromboembolic disease or estrogen-sensitive malignancy, and justify the chosen dose. Vermont's Department of Vermont Health Access (DVHA) publishes its preferred drug list online.

Once PA is approved, enrolled Medicaid members typically pay a nominal copay of $1 to $3 per month for a covered generic. That approval is usually valid for 12 months before renewal is required. The Medicaid Drug Rebate Program, administered by CMS, mandates manufacturer rebates that further reduce net cost to state programs.

The Endocrine Society's 2022 clinical practice guideline on menopause hormone therapy states: "Low-dose estrogen therapy is appropriate for women with bothersome vasomotor symptoms and no contraindications, and access barriers including cost should be actively addressed by clinicians." Endocrine Society guideline, available at endocrine.org.

Vermont also participates in the federal Low Income Subsidy (LIS) program for Medicare Part D enrollees. Patients enrolled in a Part D plan that includes estradiol on its formulary pay $0 to $10 per month under full LIS. CMS Part D Low Income Subsidy details are published at cms.gov.

Is Compounded Estradiol Legal in Vermont, and What Does It Cost?

Compounded oral estradiol is legal in Vermont through 503A pharmacies. A 503A compounding pharmacy is a state-licensed, patient-specific compounder operating under FDA oversight and Vermont Board of Pharmacy rules. These pharmacies may prepare oral estradiol in custom doses, flavored suspensions, or strengths not commercially available (for example, 0.25 mg tablets for patients requiring very low doses). FDA's guidance on 503A pharmacy compounding is published at fda.gov.

Cost for compounded oral estradiol varies by pharmacy and formulation. Some telehealth programs that partner with 503A pharmacies offer compounded estradiol at $0 per month to qualifying patients through manufacturer assistance, grant funding, or internal subsidy models. Others charge $20 to $60 per month depending on the dose and base. The FDA's overview of compounding regulations under the Drug Quality and Security Act applies directly to Vermont 503A pharmacies.

Vermont law does not permit 503B outsourcing facilities to compound estradiol for individual outpatient prescriptions. Only 503A pharmacies fulfill that role for individual Vermont patients. Vermont Board of Pharmacy licensing requirements are outlined at vtprofessionals.org.

One practical consideration: compounded estradiol is not FDA-approved, meaning bioequivalence data is not required. The North American Menopause Society (NAMS) 2022 position statement notes that "custom-compounded hormone therapy lacks the rigorous testing of FDA-approved products and should not be considered equivalent in safety or efficacy." NAMS position statement available at menopause.org.

Compounded options make clinical sense primarily when a patient cannot tolerate commercial tablet fillers, requires a non-standard dose, or faces cost barriers that approved generics cannot resolve.

What Insurance Plans Cover Oral Estradiol in Vermont?

Most private insurance plans sold through Vermont Health Connect (the state's ACA marketplace) cover generic oral estradiol on Tier 1 or Tier 2. Tier 1 generic copays in Vermont ACA plans typically range from $0 to $15 per month. Employer-sponsored plans in Vermont follow similar formulary conventions. The ACA requires non-grandfathered plans to cover preventive services without cost-sharing; for postmenopausal women, hormone therapy for osteoporosis prevention may trigger no-cost coverage under USPSTF B-rated recommendations.

Blue Cross Blue Shield of Vermont (BCBSVT) and MVP Health Care are the two largest insurers active in the Vermont individual and small-group market. Both list estradiol tablets on their standard formularies as preferred generics. Prior authorization is not routinely required by BCBSVT for standard doses (0.5 mg to 2 mg once daily) when prescribed for menopause symptoms, though step therapy applying a transdermal trial first may appear in some employer plan designs.

Patients covered by TRICARE (federal military insurance) also have access to estradiol at no cost through the TRICARE mail-order pharmacy, which serves Vermont residents. TRICARE formulary details are published at health.mil.

The Women's Health and Cancer Rights Act and subsequent parity regulations do not directly govern hormone therapy access, but Vermont state mental health parity law (17 V.S.A. § 4089h) sets a framework that insurers cite when determining whether HRT-related PA criteria are clinically equivalent to those applied in other chronic disease categories. Vermont statute is accessible via the Vermont Legislature website.

If an insurer denies a claim for estradiol, Vermont law provides an external appeals process administered by the Department of Financial Regulation. That process has a 72-hour expedited track for urgent clinical situations. Vermont Department of Financial Regulation insurance appeals guidance is at dfr.vermont.gov.

Can I Get Oral Estradiol Through Telehealth in Vermont?

Telehealth prescribing of oral estradiol is permitted in Vermont. Vermont law allows licensed physicians, nurse practitioners, and physician assistants to prescribe non-controlled medications including estradiol following a telehealth evaluation, provided they establish a valid patient-provider relationship. Vermont's telehealth statutes are codified at 26 V.S.A. § 1367.

HealthRX and other telehealth platforms serving Vermont patients complete an asynchronous or synchronous intake that covers personal and family history, current medications, and contraindication screening before issuing a prescription. That prescription routes to the patient's preferred local pharmacy or a mail-order partner. Turnaround from intake to prescription is typically 24 to 72 hours. The Federation of State Medical Boards' 2020 telemedicine guidelines, which Vermont's medical board cites, are published at fsmb.org.

Telehealth visits for HRT in Vermont typically cost $30 to $150 depending on the platform and whether the patient has insurance that covers telehealth consults. Many plans cover telehealth at parity with in-person visits under Vermont's telemedicine parity law (8 V.S.A. § 4100k). Vermont telemedicine parity statute: legislature.vermont.gov.

The clinical encounter for estradiol prescribing includes a baseline symptom assessment (commonly the Menopause Rating Scale or Greene Climacteric Scale), cardiovascular risk stratification, and documentation of uterine status, since patients with an intact uterus require concurrent progestogen to prevent endometrial hyperplasia. A 2020 Cochrane review confirms that unopposed estrogen in women with an intact uterus significantly increases endometrial cancer risk.

What Are the Cheapest Ways to Get Oral Estradiol in Vermont?

The lowest out-of-pocket cost for oral estradiol in Vermont in 2026 typically comes from one of three routes: a 503A compounding pharmacy subsidy program ($0/month for qualifying patients), a 340B FQHC prescription (under $5/month), or a GoodRx coupon at a high-volume retail pharmacy ($10 to $15/month for a 30-day supply of 1 mg tablets).

For patients with Medicare Part D and full Low Income Subsidy, the monthly cost is $0 to $4 under most plans. CMS Medicare Part D formulary requirements are published at cms.gov.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists estradiol 1 mg tablets at approximately $7 for 30 tablets plus a dispensing fee, and ships to Vermont. That pricing often undercuts local retail even after applying coupon cards. Cost Plus Drugs pricing methodology has been reviewed in a 2023 JAMA Health Forum analysis.

The Pfizer and Teva patient assistance programs do not typically apply to off-patent generic estradiol, since those products are not branded. However, NovaBay Pharmaceuticals and other specialty formulators that market branded versions occasionally offer manufacturer cards reducing the price to $0 to $25 for commercially insured patients who do not qualify for government assistance. FDA's orange book lists approved estradiol tablet manufacturers.

HealthRX Vermont Cost Decision Framework for Oral Estradiol

Use this sequence to find the lowest cost:

1. Vermont Medicaid eligible? Apply for PA first. Cost: $1 to $3/month after approval.
2. Medicare Part D with LIS? Confirm estradiol is on your plan's formulary. Cost: $0 to $4/month.
3. ACA plan through Vermont Health Connect? Check Tier 1 copay. Cost: $0 to $15/month.
4. No insurance or high-deductible plan? Compare GoodRx, RxSaver, and Cost Plus Drugs. Cost: $7 to $18/month.
5. Cannot tolerate commercial tablets or need non-standard dose? Ask a HealthRX clinician whether a 503A-compounded option or FQHC referral applies. Cost: $0 to $40/month.

Clinical Background: Why Oral Estradiol Is Prescribed

Oral estradiol is a bioidentical form of the primary human estrogen, 17-beta-estradiol. The FDA approved oral estradiol tablets for treatment of moderate-to-severe vasomotor symptoms of menopause, vulvovaginal atrophy, and, at low doses, prevention of postmenopausal osteoporosis. FDA prescribing information is accessible through the accessdata portal.

The Women's Health Initiative (WHI) remains the largest randomized controlled trial of postmenopausal hormone therapy. The 2002 JAMA publication (N=16,608) found that combined estrogen-progestogen therapy increased breast cancer risk (hazard ratio 1.26 to 95% CI 1.00 to 1.59) but reduced colorectal cancer risk (HR 0.63) and fracture risk (HR 0.76). WHI primary results: JAMA 2002, PMID 12117397.

Oral estradiol differs pharmacokinetically from transdermal estradiol. First-pass hepatic metabolism converts oral estradiol to estrone at roughly a 5:1 ratio, raising sex-hormone-binding globulin and C-reactive protein more than transdermal routes do. A 2016 Cochrane review comparing oral versus transdermal HRT routes found that transdermal delivery carries a lower venous thromboembolism risk than oral administration.

For healthy women under 60 within 10 years of menopause onset, the NAMS 2022 position statement and the British Menopause Society both affirm that the benefit-risk ratio of oral estradiol is favorable for managing bothersome vasomotor symptoms. NAMS 2022 Hormone Therapy Position Statement, menopause.org. British Menopause Society consensus statement, academic.oup.com.

Typical starting doses are 0.5 mg or 1 mg once daily, with titration to 2 mg if symptoms are not controlled at 12 weeks. Patients with an intact uterus must receive concurrent progestogen, most commonly micronized progesterone 100 mg to 200 mg daily or medroxyprogesterone acetate 2.5 mg daily, to prevent endometrial hyperplasia. A 2018 RCT in Menopause (PMID 29738330) confirmed that micronized progesterone at 100 mg nightly is sufficient for endometrial protection with oral estradiol up to 2 mg.

Bone protection data are relevant for Vermont clinicians: the USPSTF recommends screening for osteoporosis in women 65 and older and in younger postmenopausal women with risk factors. Estradiol at 0.5 mg daily has been shown to maintain lumbar spine bone mineral density in early postmenopause. USPSTF osteoporosis screening recommendation, A/B grade, uspreventiveservicestaskforce.org. A 2016 RCT (PMID 27380343) confirmed bone density preservation with low-dose oral estradiol 0.5 mg in postmenopausal women over 24 months.

Contraindications include known or suspected breast cancer, estrogen-dependent neoplasia, undiagnosed abnormal uterine bleeding, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease, liver dysfunction, and known hypersensitivity to estradiol or tablet excipients. FDA prescribing information contraindications section: accessdata.fda.gov.

Vermont-Specific Pharmacy Access Points

Vermont has 49 community pharmacies and 12 hospital outpatient pharmacies, distributed across Chittenden, Washington, Windham, Windsor, and Rutland counties. Rural areas including the Northeast Kingdom are served by mail-order partners and telehealth platforms that ship to Vermont addresses. Vermont Board of Pharmacy pharmacy directory: vtprofessionals.org.

The Vermont Chronic Care Initiative (VCCI) coordinates care for Medicaid members with multiple chronic conditions, including perimenopausal patients managing cardiovascular risk factors alongside menopause symptoms. VCCI care managers can assist with PA paperwork for estradiol. DVHA VCCI program information: dvha.vermont.gov.

Mail-order 90-day supplies are available through Magellan Rx (contracted with several Vermont employer plans), Express Scripts, and OptumRx. A 90-day mail supply of estradiol 1 mg typically costs $20 to $35 under most Vermont employer plans, compared with three 30-day retail fills totaling $30 to $60. OptumRx mail pharmacy information: optumrx.com, referenced against CMS formulary file requirements at cms.gov.

Kinney Drugs, the regional chain with 97 locations across Vermont and upstate New York, participates in GoodRx and offers its own savings program. Patients at Kinney locations in St. Johnsbury, Newport, and other Northeast Kingdom towns pay the same GoodRx-adjusted price as Burlington patients. GoodRx pricing methodology is described in a 2021 JAMA Internal Medicine analysis of cash-pay prescription pricing variation.

Monitoring and Follow-Up After Starting Oral Estradiol in Vermont

Starting oral estradiol requires a follow-up plan. Most Vermont clinicians and telehealth platforms schedule a 6 to 12 week check-in to assess symptom response, side effects (breast tenderness, bloating, spotting), and blood pressure. Routine laboratory monitoring of estradiol serum levels is not required for symptomatic management at standard doses, though some clinicians order a level at 3 months to confirm absorption. The Endocrine Society 2022 guideline states that serum estradiol monitoring is optional but may guide dose adjustment in non-responders.

Mammography and cervical cancer screening schedules do not change based solely on estradiol initiation. Women on combined estrogen-progestogen therapy should continue annual or biennial mammography per USPSTF age-based guidelines. USPSTF breast cancer screening recommendation, uspreventiveservicestaskforce.org.

Patients should report unexpected vaginal bleeding promptly. Any bleeding in a postmenopausal woman on estrogen-only therapy (without progestogen) warrants endometrial evaluation, typically via transvaginal ultrasound with endometrial stripe measurement. An endometrial thickness of <4 mm has a negative predictive value of 99% for endometrial carcinoma. A 2018 systematic review in Obstetrics and Gynecology (PMID 29521832) confirmed the 4 mm threshold.

Annual cost projection for an uninsured Vermont patient on oral estradiol 1 mg daily: $120 to $216 per year at retail GoodRx pricing, or $84 per year through Cost Plus Drugs (30 tablets x 12 months at ~$7), plus one telehealth visit per year at $30 to $150. Total annual out-of-pocket: $114 to $366. That is the realistic range, not a best-case scenario.